CCM
EXAS

Credo Capital Management’s Exact Sciences EXAS Stock Holding History

Credo Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-635
Closed -$7K – 174
2013
Q3 		$7K Sell
635
-361
-36% -$4.63K 0.01% 165
2013
Q2 		$14K Buy
+996
New +$10.8K 0.01% 138

Other funds holding EXAS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return

Credo Capital Management's EXAS Position: Q4 2013 in Review

Credo Capital Management sold out of Exact Sciences (EXAS) in Q4 2013, closing a stake of 635 shares — an estimated $7K sold.

Credo Capital Management first reported a position in EXAS in Q2 2013 and held it in 2 quarters. The position peaked at $14K in Q2 2013. 131 funds tracked by Wall St. Rank hold EXAS as of Q4 2013.

  • Credo Capital Management reported no remaining Exact Sciences position as of Q4 2013 after selling out during the quarter.
  • Credo Capital Management sold 635 Exact Sciences shares in Q4 2013, an estimated $7K.
  • Credo Capital Management first reported a position in Exact Sciences in Q2 2013 and held it in 2 quarters.
  • Credo Capital Management's Exact Sciences position peaked at $14K in Q2 2013.
  • 131 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.